4DMEDICAL LIMITED (4DX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

4DX

4DX - 4DMEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.06
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

4DMedical is a medical technology company specialising in respiratory imaging and analysis for lung disease. The company has facilities in Melbourne and Los Angeles and listed on the ASX in 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.42

31 Aug
2026

-0.220

OPEN

$3.68

-6.04%

HIGH

$3.73

5,037,297

LOW

$3.41

TARGET
$4.50 31.6% upside
OTHER COMPANIES IN THE SAME SECTOR
AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
4DX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 3.0 - 5.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-3.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx7.1 M
Book Value Per Share xxxxxxxxxxxxxxx28.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-31.3 M
Net Profit Margin xxxxxxxxxxxxxxx-2,895.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-174.43 %
Return on Invested Capital xxxxxxxxxxxxxxx-170.50 %
Return on Assets xxxxxxxxxxxxxxx-88.86 %
Return on Equity xxxxxxxxxxxxxxx-174.43 %
Return on Total Capital xxxxxxxxxxxxxxx-47.50 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-32.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx278 M
Price To Book Value xxxxxxxxxxxxxxx15.91

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx17.92 %
Cost of Goods Sold xxxxxxxxxxxxxxx45 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx19 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

03/06/2026

5

Sell

$3.00

-12.28%

Ord Minnett assesses the updates from 4DMedical and reviews the US commercialisation opportunity and suspects a risk investors are over estimating the core nuclear VQ market, with analysis indicating around 440,000 scans per annum compared with the 1m estimated by the company.

Based on its analysis of the epidemiological industry data, the broker estimates pulmonary embolism, CTEPH and lung surgery are the key drivers of current US VQ scan volumes.

Upside will hinge on the company's ability to disrupt the CTPA market, which Ord Minnett considers a "tougher proposition" given the advantages of CTPA in an acute care setting.

Amid limited valuation support the broker remains cautious about the stock and retains a Sell rating with a $3 target.

FORECAST
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -7.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

4DX STOCK CHART

FNArena News on 4DX

1
FNArena Corporate Results Monitor – 31-08-2026

Aug 31 2026 - Australia
2
Rudi’s View: Upside Risk In Crowded Shorts

Aug 12 2026 - Rudi's View
3
Rudi’s View: All-Weathers In The Age Of Disruption

Jul 22 2026 - Rudi's View
4
Next Week At A Glance – 8-12 Jun 2026

Jun 05 2026 - Weekly Reports
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals